Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2/HO-1 Signaling Pathway

Figure 4

Effects of ASIV on the inhibition of H9c2 cell hypertrophy induced by Ang II. (a) To determine the optimal concentration and time of Ang II treatment, H9c2 cardiomyocytes were treated with 0, 0.01, 0.1, 1, 10, or 100 μM of Ang II for 12, 24, or 48 h, followed by CCK8 analysis. (b) To investigate the cytotoxicity of ASIV, H9c2 cardiomyocytes were treated with 0, 6.25, 12.5, 25, 50, or 100 μM of ASIV for 24 h, followed by CCK8 analysis. (c) After stimulation with 1 μM of Ang II, H9c2 cardiomyocytes were treated with different concentrations of ASIV, and cell viability was measured with CCK8 assays. (d, e) Representative images and quantification of cardiomyocyte areas evaluated after α-actinin immunostaining. Scale bar, 20 μm. . (f) The expression of a cardiac hypertrophic marker, atrial natriuretic peptide (ANP), at the mRNA level was detected by real-time fluorescence quantitative PCR. (g, h) The expression of ANP at the protein level was detected by Western blotting. vs. the control group; ^# vs. the Ang II group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)